What is Climb Bio, Inc.'s R&D?

Climb Bio, Inc. (CLYM) reported R&D of $9.37M in Q1 2026.

How has Climb Bio, Inc.'s R&D changed year-over-year?

Climb Bio, Inc.'s R&D decreased by 45.9% year-over-year, from $17.33M to $9.37M.

What is the long-term trend for Climb Bio, Inc.'s R&D?

Over 4 years (2021 to 2025), Climb Bio, Inc.'s R&D has grown at a 19.9% compound annual growth rate (CAGR), from $22.62M to $46.71M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

Climb Bio, Inc. CLYM R&D

R&D at other companies

Bristol-Myers SquibbBMY

$2.65B+17.4%

AmgenAMGN

$1.72B+15.7%

Vera TherapeuticsVERA

$86.01M+108%

Kyverna Therapeutics, Inc.KYTX

$30.07M-19.7%

Cullinan Therapeutics, Inc.CGEM

$42.12M+1.6%

Jade Biosciences, Inc. Common StockJBIO

$36.05M+80.1%

Other financials

Income statement

See full

Operating income-$15.2M+33.9%

Net income-$13.7M+34.0%

EPS (diluted)-$0.20+35.5%

Balance sheet

See full

Cash & equivalents$8.4M-71.2%

Total debt$479.0K+1.1%

Total equity$148.1M-23.4%

Total assets$152.4M-24.1%

Cash flow

See full

Operating cash flow-$14.4M+6.8%

CapEx$109.0K—

Free cash flow-$15.6M-183%

Valuation

See full

Market cap$724.95M+787%

Enterprise value$717.07M+1,247%

Returns & leverage

See full

Return on equity-30.9%-10.3pp

Debt / equity0×0.0×

Current ratio27.9×+13.6×

Where this comes from

Reported directly by Climb Bio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Climb Bio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Climb Bio, Inc.'s r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Climb Bio, Inc.'s R&D?: Climb Bio, Inc. (CLYM) reported R&D of $9.37M in Q1 2026.
How has Climb Bio, Inc.'s R&D changed year-over-year?: Climb Bio, Inc.'s R&D decreased by 45.9% year-over-year, from $17.33M to $9.37M.
What is the long-term trend for Climb Bio, Inc.'s R&D?: Over 4 years (2021 to 2025), Climb Bio, Inc.'s R&D has grown at a 19.9% compound annual growth rate (CAGR), from $22.62M to $46.71M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.